• News
  • Film and TV
  • Music
  • Tech
  • Features
  • Celebrity
  • Politics
  • Weird
  • Community
  • Advertise
  • Terms
  • Privacy & Cookies
  • LADbible Group
  • LADbible
  • SPORTbible
  • GAMINGbible
  • Tyla
  • UNILAD Tech
  • FOODbible
  • License Our Content
  • About Us & Contact
  • Jobs
  • Latest
  • Topics A-Z
  • Authors
Facebook
Instagram
X
Threads
TikTok
YouTube
Submit Your Content
Controversy surrounding life-saving drug that patients only need one dose of but it costs over $2,000,000

Home> News> Health

Published 16:15 9 Jan 2025 GMT

Controversy surrounding life-saving drug that patients only need one dose of but it costs over $2,000,000

Imagine needing a medical treatment that could change your child's life, but it costs a jaw-dropping amount of money

Jen Thomas

Jen Thomas

Imagine how it feels knowing that just one dose of a medication could change your child's life, but it costs more than $2 million.

It sounds like something from a cruel futuristic film, but this is the very real problem facing patients and their parents today.

The price of medication has long caused upset, with some Americans racking up thousands in debt for treatment.

The drug in question is called Zolgensma, and it is a one-time-only gene therapy treatment for children under two years old.

Advert

It is used for the treatment of a condition called spinal muscular atrophy, SMA for short.

It works by treating the genetic root cause of SMA, as it replaces a 'missing or nonworking SMN1 gene' with a working copy of a human SMN gene.

It is done so through the use of a carrier called a 'vector'.

Zolgensma costs over $2 million (Getty Stock Image)
Zolgensma costs over $2 million (Getty Stock Image)

Advert

Put simply, the carrier for this treatment is a virus that has had its DNA removed.

The DNA is then replaced with the correct working gene.

Patients don't get sick from the virus, and instead it travels through the body to deliver the new gene to where it's needed. It then tells the body to make the new working protein instead.

The vectors are then broken down and shed from the body.

Advert

The downside is, it costs an eyewatering $2.1 million for a single treatment. Families of patients are infuriated by how much it costs, and are calling for the price to be lowered.

In the UK in 2021, a deal was struck meaning they could access the drug at a cheaper price, so 80 babies a year could benefit from it.

The staggering price of the drug, which is sold by Novartis, was supported by independent body Institute for Clinical and Economic Review (ICER), which suggests fair prices for medication.

Dr. Steven D. Pearson, then-president of ICER, said of Zolgensma's $2.1 million price tag when it was announced back in 2019: "Zolgensma is dramatically transforming the lives of families affected by this devastating disease, and given the new efficacy data for the pre-symptomatic population, the price announced today falls within the upper bound of ICER’s value-based price benchmark range."

Advert

The drug could be life-saving (Getty Stock Image)
The drug could be life-saving (Getty Stock Image)

Something else that has ruffled feathers, is the early stage development of Zolgensma was funded and financed by the National Institutes of Health and several charities.

Many charities based in the US such as Sophia’s Cure, Cure SMA, Getty Owl Foundation, Fighting SMA, Jadon’s Hope Foundation, the Gwendolyn Strong Foundation, and Miracle for Madison used donations to invest in clinical trials and to help research.

A previous medication used for treating SMA, Spinraza, is taken four times a year for life.

Advert

Spinraza is priced at $750,000 for the first year, with each following year costing $350,000 per year.

A decade of treatment would set you back something close to $4 million.

Horrifyingly, when it comes to pricing a drug, many companies calculate how many years of life the patient gains.

Novartis purchased Zolgensma when they acquired the firm AveXis for a whopping $8.7 billion.

Advert

What's worse, most health insurance schemes won't insure one-time genetic treatments such as this due to the price tag.

Novartis offers payments in instalments, at $425,000 a year.

They have also said they will give partial refunds if the treatment doesn't work.

UNILAD has contacted Novartis for a comment.

Featured Image Credit: Getty Images/Ewerton Manzotte/Getty Images/Bevan Goldswain

Topics: Health, Parenting, Money

Jen Thomas
Jen Thomas

Jen Thomas is a freelance journalist and radio presenter for Magic Radio and Planet Rock, specialising in music and entertainment writing.

X

@jenthomasradio

Advert

Advert

Advert

Choose your content:

8 hours ago
9 hours ago
  • 8 hours ago

    Chipotle customer finds receipt from 10 years ago and the comparison is making people want to cry

    Chipotle customers are understandably upset

    News
  • 8 hours ago

    100-year-old identical twins reveal secret to long life after celebrating milestone

    Bernice Frank and Gloria Lipman shared their wisdom for reaching 100-years-old

    News
  • 9 hours ago

    Forensic psychiatrist gives chilling theory behind Bryan Kohberger’s motive after he confessed to Idaho murders

    Bryan Kohberger pleaded guilty to murder earlier this week

    News
  • 9 hours ago

    Body found in search for man who vanished on vacation as police release chilling details

    Brian Tarrence was with his wife in Turks and Caicos before being reported missing days later

    News
  • Nokia makers launch a new Barbie flip phone that can only text and call but people think it has a great purpose